Efficacy and safety of SARS-CoV-2 vaccination in patients with inflammatory bowel disease on immunosuppressive and biological therapy: Prospective observational studyObservational Study Published on 2022-09-022022-10-05 Journal: PLoS ONE [Category] SARS, 임상, 진단, [키워드] adverse event Anaphylactic reaction antibody BNT162b2 combination therapy COVID-19 COVID-19 pandemic dose Efficacy and safety eligible patient evaluate evaluated event geometric group Health immunosuppressive indicated Inflammatory bowel disease Local majority MONITOR Patient patients Prospective prospective observational study SARS-CoV-2 SARS-CoV-2 IgG antibody SARS-CoV-2 vaccination significant difference therapy treated U/mL vaccination vaccination against COVID-19 Vaccine vaccine administration [DOI] 10.1371/journal.pone.0273612 PMC 바로가기 [Article Type] Observational Study
A systematic review and meta-analysis of immune response against first and second doses of SARS-CoV-2 vaccines in adult patients with hematological malignancies혈액암이 있는 성인 환자의 SARS-CoV-2 백신 1차 및 2차 접종에 대한 면역 반응의 체계적인 검토 및 메타 분석Review Published on 2022-09-012022-09-11 Journal: International immunopharmacology [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술, [키워드] 95% confidence interval 95%CI affected affecting anti-CD20 therapy antibody Antibody detection Antibody Response article booster dose booster doses calculated Cancer patients chronic lymphocytic leukemia CLL Complete conducted coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 vaccination COVID-19 vaccine COVID-19 vaccines develop Diagnosis disease doses evaluate first dose Google Google Scholar healthy subject healthy subjects Hematological malignancies Hematological malignancy higher risk highlight highlighting immune response Immunity immunization Immunocompromised immunogenicity immunosuppressive IMPROVE kinase inhibitors less leukemia lowest Lymphocytic leukemia lymphoma malignancy measure Meta-analysis mRNA mRNA-1273 Myeloma Patient Primary outcome response rate SARS-CoV-2 SARS-CoV-2 vaccine second dose secondary outcome Secondary outcomes seropositive Seropositivity severe coronavirus disease solid tumor solid tumors status subgroup subtype systematic review the disease the vaccine tumors tyrosine tyrosine kinase inhibitor tyrosine kinase inhibitors Vaccine vaccine dose vaccine's immunogenicity Web of Science [DOI] 10.1016/j.intimp.2022.109046 PMC 바로가기 [Article Type] Review
Antibody response to BNT162b2 SARS-CoV-2 mRNA vaccine in adult patients with systemic sclerosisArticle Published on 2022-09-012022-11-15 Journal: Clinical Rheumatology [Category] COVID19(2023년), SARS, 진단, [키워드] 95% CI Affect Antibody titer BNT162b2 CCS Clinical characteristics Cohort Comorbidity Corticosteroids COVID-19 difference disease evaluated Fisher exact test healthy control humoral Humoral response Immunosuppression immunosuppressive Immunosuppressive treatment IQR Logistic regression analysis low dose Mann-Whitney methotrexate mRNA vaccination mRNA vaccine MTX Patient patients patients treated Point reduced Regression model risk RTX SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 vaccine second dose serological response seropositive Seropositivity serum IgG severe disease course student systemic Systemic sclerosis t-test therapy Treatment untreated patient vaccination Vaccine vaccine-induced antibody [DOI] 10.1007/s10067-022-06219-7 PMC 바로가기
Identification of a novel immune-inflammatory signature of COVID-19 infections, and evaluation of pharmacokinetics and therapeutic potential of RXn-02, a novel small-molecule derivative of quinoloneResearch article Published on 2022-09-012022-10-05 Journal: Computers in biology and medicine [Category] COVID19(2023년), SARS, 변종, 신약개발, 치료기술, 치료제, [키워드] A549 activity acute respiratory syndrome addition Analysis AUC binding binding affinity Bioinformatics analysis candidate caused Cell cell line clinical investigation Colon conducted coronavirus Coronavirus disease 2019 COVID-19 COVID-19 (Coronavirus disease 2019) COVID-19 infections dataset drug drug target effector memory Efficacy evaluated exhibited FIVE gene signature global pandemic human lung IC50 identification immune immunomodulation immunomodulatory immunosuppressive in vitro in vivo Inflammation Inflammatory Lungs peak plasma concentration pharmacokinetics positive-sense RNA virus respiratory infection SARS-CoV-2 SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) SARS-CoV-2 drug SARS-COV-2 infection SARS-CoV-2 infections SARS-CoV-2 pathogenesis SARS-CoV-2-infected patient suggested T cell therapeutic options therapeutic potential therapy threat transcriptomic translation translational vaccine candidates value [DOI] 10.1016/j.compbiomed.2022.105814 [Article Type] Research article
Different humoral but similar cellular responses of patients with autoimmune inflammatory rheumatic diseases under disease-modifying antirheumatic drugs after COVID-19 vaccinationArticle Published on 2022-09-012022-11-15 Journal: RMD Open [Category] SARS, 진단, [키워드] activated Activation antibody Autoimmune Autoimmune diseases Cellular immune response cellular response Combination correlated COVID-19 COVID-19 vaccination csDMARD cytokine cytokine profile drug drugs evaluated female first vaccination Frequency Heterologous highest humoral IgG immunosuppressive immunosuppressive therapy Inflammatory inhibitor investigated majority marker median age medications methotrexate monotherapy mRNA-based vaccine MTX Neutralising Antibodies neutralising antibody no difference not significant outcome Patient psoriatic arthritis quantification receiving rheumatic disease rheumatoid arthritis SARS-CoV-2 second vaccination Seroconversion spike-protein spondyloarthritis T-cell T-cell immunity T-lymphocyte T-lymphocyte subsets Therapies therapy titre treated vaccination [DOI] 10.1136/rmdopen-2022-002293 PMC 바로가기
Immunogenicity and reactogenicity of an inactivated SARS-CoV-2 vaccine (BBV152) in children aged 2-18 years: interim data from an open-label, non-randomised, age de-escalation phase 2/3 studyClinical Trial Published on 2022-09-012022-10-05 Journal: The Lancet. Infectious Diseases [Category] COVID19(2023년), SARS, 임상, 진단, [키워드] 95% CI Administered Adults adverse event age all age group antibody baseline Bharat Biodefense children clinical conducted COVID-19 vaccine curtail deaths decrease demonstrated dose Efficacy eight eligible Endpoint enrolled female Fever for inclusion geometric mean GMT ratio GMTs group groups healthy children hospital Hyderabad immunogenicity immunosuppressive inactivated Inactivated vaccine India Infection injection site pain intramuscular dose less Local local reaction male Mild Mild-to-moderate multicentre neutralisation test neutralising antibody response neutralising antibody titre no difference Open-label Pain pandemic participant Phase 2 study phase 2/3 platform positive PRNT Reactions reactogenicity reduction Registered registry reported safety profile SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 nucleic acid SARS-CoV-2 vaccine second dose Serious Adverse Events seroconverted serology test serum sample severity of COVID-19 susceptible Symptom three group titre Trial were excluded Withdrawal [DOI] 10.1016/S1473-3099(22)00307-3 PMC 바로가기 [Article Type] Clinical Trial
Differential Impact of SARS-CoV-2 Isolates, Namely, the Wuhan Strain, Delta, and Omicron Variants on ErythropoiesisArticle Published on 2022-08-312022-11-16 Journal: Microbiology Spectrum [Category] SARS, 변종, [키워드] ACE2 Affect Blood blood circulation Bone marrow CD45 CD8 Cell COVID-19 patient COVID-19 patients degranulation Delta disease severity dominant erythropoiesis erythropoiesis. Express expressing expression Frequency function functions granzyme hallmark Hematopoiesis hypoxia immature immunosuppressive immunosuppressive properties Impact impair in vitro investigated omicron oxygen Patient prevalent provide RBC RBCs reactive oxygen specy receptor red blood cell reversed ROS SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 variant SARS-CoV-2 variants significantly strain subpopulation suppress T cell the SARS-CoV-2 these cell tissues TMPRSS2 Transmissibility variant variants Wuhan Wuhan strain [DOI] 10.1128/spectrum.01730-22 PMC 바로가기
Tocilizumab, netakimab, and baricitinib in patients with mild-to-moderate COVID-19: An observational study경증에서 중등도의 COVID-19 환자에 대한 Tocilizumab, netakimab 및 baricitinib: 관찰 연구Observational Study Published on 2022-08-242022-09-12 Journal: PLoS ONE [Category] SARS, 임상, 진단, [키워드] adults hospitalized anti-IL-6R antibody Anticoagulant Antiviral average Baricitinib benefit blockers Blood C-reactive protein (CRP Clinical outcome Combination comparable COVID-19 CRP level Dexamethasone discharged dose Efficiency group groups hospital hospitalized patient Hydroxychloroquine IL-17A immunosuppressive inflamed tissues Inflammation Inflammatory marker JAK1/JAK2 inhibitor lactate dehydrogenase LDH marker Mild-to-moderate mild-to-moderate disease Mortality neutrophil neutrophil count Neutrophil-to-lymphocyte ratio NEWS2 observation Observational cohort study Patient previous study remained safety profile SARS-CoV-2 severe COVID-19 significant decrease significant increase significantly significantly increased Standard-of-care therapeutic therapy Tocilizumab treated [DOI] 10.1371/journal.pone.0273340 PMC 바로가기 [Article Type] Observational Study
Structural basis for Sarbecovirus ORF6 mediated blockage of nucleocytoplasmic transport Research Published on 2022-08-152022-10-05 Journal: Nature Communications [Category] SARS, 변종, 진단, 치료제, [키워드] accessory protein Acidic addition antagonistic antagonists binding blockade C-terminal cells Community complex crystal structure expression hydrophobic identify immunosuppressive in vitro Interaction interferon interferon antagonism International methionine molecular basis mRNA Mutagenesis mutated Mutation ORF6 Orf9b peptide residue reveal salt-bridge SARS-CoV SARS-CoV-2 SARS-CoV-2 variant Stat1 the binding affinity the spike protein Transport VOCs [DOI] 10.1038/s41467-022-32489-5 [Article Type] Research
Humoral and cellular response in convalescent COVID-19 lupus patients회복기 COVID-19 루푸스 환자의 체액 및 세포 반응Article Published on 2022-08-122022-09-11 Journal: Scientific Reports [Category] SARS, 진단, 치료기술, 치료법, 치료제, [키워드] accumulated adaptive Analysis analyzed antibodies antibody Antibody Response Antibody titer Antibody titers CD8 cellular response changes in collected confirmed cases confirmed COVID-19 case convalescent convalescent COVID-19 patient convalescent COVID-19 patients convalescent patient Convalescent patients COVID-19 COVID-19 disease COVID-19 incidence COVID-19 infection COVID-19 susceptibility declined decrease died dose dysregulation evaluated flow cytometry Gene expression analysis General population Health care higher risk Hospital admission humoral Humoral and cellular responses hypocomplementemia IgG antibodies immune dysregulation immune response immunological immunological profile Immunological studies Immunosuppression immunosuppressive immunosuppressive therapy impair incidence increase in Infection intensive care lack longitudinal longitudinal changes Lupus medical record memory cell Mild Patient patients PBMC PBMCs PCR-confirmed COVID-19 Prednisone predominant prospective cohort reduction required risk factor Risk factors SARS-CoV-2 IgG SARS-CoV-2 IgG antibodies SARS-CoV-2 IgG antibody severe COVID-19 disease severe disease severity Signaling SLE Surveillance susceptibility sustained Symptom symptom onset T cell Th17 Th2 response therapy were measured [DOI] 10.1038/s41598-022-17334-5 PMC 바로가기 [Article Type] Article